Published in Gene Therapy Weekly, February 5th, 1996
The cytokine interleukin 1 (IL-1) plays an important role in the pathogenesis of human RA. The naturally occurring antagonist of IL-1, recombinant human secreted interleukin 1 receptor antagonist (sIL-1ra), is a glycoprotein which competitively binds IL-1 receptors without eliciting cell activation. Previous research has shown the therapeutic benefit of systemically administering sIL-1ra for treatment of rheumatoid arthritis.
Sergei S. Makorov et al. proposed that rather than the daily systemic delivery of sIL-1ra to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.